Acquisition and Regulatory Update - Boston Scientific voluntarily withdrew and refiled its HSR Filing to allow the FTC additional time to review the proposed acquisition of Silk Road Medical [1] - The acquisition of Silk Road Medical, announced in June 2024, involves a purchase price of $27.50 per share, reflecting an enterprise value of approximately $1.16 billion [2] - The new 30-day waiting period under the HSR Act will commence on Aug 13, 2024, and expire on Sep 12, 2024 [2] Recent Acquisitions by Boston Scientific - In March 2024, the company acquired the Endoluminal Vacuum Therapy portfolio from B Braun [3] - In December 2023, Boston Scientific initiated the acquisition of Axonics for $3.7 billion, aiming to expand its urology portfolio [3] - The company also acquired Relievant Medsystems in late 2023, adding the FDA-approved Intracept Intraosseous Nerve Ablation System to its Neuromodulation portfolio [3] Industry Prospects - The global carotid artery stents market was valued at $559.7 million in 2021 and is projected to grow at a CAGR of 3% from 2022 to 2030 [4] - Growth drivers include the rising prevalence of cardiovascular diseases, technological advancements in stent design, and an aging global population [4] - Innovations such as drug-eluting and biodegradable stents are enhancing market potential [4] Price Performance - Boston Scientific's shares have gained 36.1% year-to-date, outperforming the industry's rise of 8.7% and the S&P 500's increase of 17.7% [5] Other Top-Ranked Medical Stocks - Universal Health Service (UHS) has a Zacks Rank 1 (Strong Buy) and has gained 41.1% year-to-date, surpassing the industry's 34.8% rise [6] - Quest Diagnostics (DGX) has a Zacks Rank 2 (Buy) and has gained 3.7% year-to-date, compared to the industry's 10.2% rise [6][7] - ABM Industries (ABM) has a Zacks Rank 2 (Buy) and has risen 24.1% year-to-date, outperforming the industry's 11.9% growth [7]

MARLBOROUGH, Mass., Aug. 13, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in Wells Fargo's 2024 Healthcare Conference on Wednesday, September 4, 2024.Mike Mahoney, chairman and chief executive officer, and Dr. Brad Sutton, chief medical officer, Atrial Fibrillation Solutions, will participate in a 35-minute question-and-answer session with the host analyst at approximately 8:00 a.m. ET. A live webcast and replay of the session will be accessible at htts://investors.bostons ...

U.S. stock markets have rebounded from last week’s devastations. The Wall Street rally, which started in January 2023, saw a significant change in July 2024. The rally was predominantly driven by the technology sector. An unprecedented adoption of generative artificial intelligence (AI) technology globally was the prime factor.Companies that have extensive applications of AI in their final products have become multi-baggers in the past 18 months. Stock prices of some of these companies have skyrocketed 200- ...

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?Let's take a look at what these Wall Street heavyweights have to say about Boston Scientific (BSX) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.Boston Scientific currently has an average brokerage re ...

Growth stocks are attractive to many investors, as above-average financial growth helps these stocks easily grab the market's attention and produce exceptional returns. But finding a growth stock that can live up to its true potential can be a tough task.In addition to volatility, these stocks carry above-average risk by their very nature. Also, one could end up losing from a stock whose growth story is actually over or nearing its end.However, it's pretty easy to find cutting-edge growth stocks with the he ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 1-11083 BOSTON SCIENTIFIC CORPORATION (Exact name of registrant as specified in its charter) Delaware 04-2695240 (State or other jurisdiction of incorporation or or ...

Boston Scientific Corporation (BSX) is gaining traction in the emerging markets. New regulatory approvals and accretive acquisitions bode well for long-term growth. The stock carries a Zacks Rank #2 (Buy) currently.Boston Scientific successfully continues with its expansion of operations across different geographies outside the United States. In the last reported second quarter of 2024, despite geopolitical weaknesses, the emerging market registered sturdy growth, primarily banking on continued broad-based ...

2024 has been a great year for U.S. indices, with the benchmark S&P 500 posting new all-time highs 38 times so far. The rally has been primarily driven by the tech sector, focusing on artificial intelligence (AI). Several record-breaking stocks have seen triple-digit returns.However, the markets appear to have taken a summer breather in July. This raises the question of whether it’s time to buy the dip under the theory that record-breaking stocks have more upside ahead.While AI stocks have been the leader i ...

Core Insights - Boston Scientific Corporation (BSX) reported adjusted earnings per share (EPS) of 62 cents for Q2 2024, a 16.9% increase year-over-year, surpassing Zacks Consensus Estimate by 6.9% and exceeding its own guidance range of 57-59 cents [1] - The company achieved revenues of $4.12 billion in Q2 2024, reflecting a 14.5% year-over-year increase on a reported basis and 16.1% on an operational basis, exceeding Zacks Consensus Estimate by 2.5% [2] Revenue Performance - Q2 revenues rose 16.9% in the United States and 13.7% in the EMEA region, with Latin America and Canada seeing a 15.3% increase [3] - Emerging markets reported a revenue growth of 14.8% [3] Segment Analysis - Boston Scientific reorganized its operations into two segments: MedSurg and Cardiovascular, with Cardiovascular generating the most revenue [4] - Cardiovascular sales reached $2.05 billion, up 22% year-over-year, while MedSurg's Endoscopy segment generated $676 million, reflecting a 7.9% organic growth [4] Margin and Cost Analysis - Gross margin contracted by 143 basis points to 69.2%, with a 20% increase in the cost of products sold [5] - Adjusted operating margin expanded by 189 basis points to 24.6% [5] Guidance and Projections - The company raised its full-year net sales growth guidance to approximately 13.5-14.5% on a reported basis and 13-14% on an organic basis [7] - For Q3 2024, Boston Scientific estimates revenue growth of 13-15% and adjusted EPS in the range of 57-59 cents [8] Market Position and Outlook - The strong Q2 performance and raised guidance are expected to bolster investor confidence in Boston Scientific's stock [9] - The company continues to gain market share across all geographic regions despite macroeconomic challenges [9]

Key TakeawaysBoston Scientific's second-quarter earnings and revenue got a boost from high demand for its heart devices.Sales of cardiovascular products made up more than half of the company's revenue in the period.Boston Scientific raised its full-year adjusted earnings per share (EPS) and revenue growth estimates. Boston Scientific (BSX) posted an increase in second-quarter earnings and sales on the back of growing demand for its heart devices. The medical device maker recorded adjusted earnings per share ...